Výsledky vyhledávání

Akademický článek

Overall and complete response rates as potential surrogates for overall survival in relapsed/refractory multiple myeloma.

Autor: Daniele P; Purple Squirrel Economics, a Cytel Company, Montreal, QC H3J 1M1, Canada., Mamolo C; Previously of Pfizer Inc., Groton, CT 06340, USA., Cappelleri JC; Pfizer Inc., Groton, CT 06340, USA., Bell T; Previously of Pfizer Inc., New York, NY 10017, USA., Neuhof A; Pfizer Pharma GmbH, 10785, Berlin, Germany., Tremblay G; Purple Squirrel Economics, a Cytel Company, Montreal, QC H3J 1M1, Canada., Musat M; Purple Squirrel Economics, a Cytel Company, New York, NY 10010, USA., Forsythe A; Purple Squirrel Economics, a Cytel Company, New York, NY 10010, USA.

Publikováno v: Future oncology (London, England) [Future Oncol] 2023 Feb; Vol. 19 (6), pp. 463-471. Date of Electronic Publication: 2023 Apr 21.

Zobrazit plný text záznamu

Akademický článek

Characterizing the Patient Journey in Multiple Myeloma: Qualitative Review.

Autor: Lyall M; RTI Health Solutions, Manchester, United Kingdom., Crawford R; RTI Health Solutions, Manchester, United Kingdom., Bell T; SpringWorks Therapeutics, Stamford, CT, United States., Mamolo C; Pfizer Inc, Groton, CT, United States., Neuhof A; Pfizer Pharma GmbH, Berlin, Germany., Levy C; RTI Health Solutions, Manchester, United Kingdom., Heyes A; RTI Health Solutions, Manchester, United Kingdom.

Publikováno v: JMIR cancer [JMIR Cancer] 2022 Sep 22; Vol. 8 (3), pp. e39068. Date of Electronic Publication: 2022 Sep 22.

Zobrazit plný text záznamu

Treatment Patterns and Outcomes among Adults Admitted to Hospital in the United Kingdom (UK) due to Plaque or Erythrodermic Psoriasis

Autor: Schaefer, C, Mamolo, C, Cappelleri, J C, Daniel, S, Le, C, Tatulych, S, Griffiths, C E M, Hampton, P J

Publikováno v: Schaefer, C, Mamolo, C, Cappelleri, J C, Daniel, S, Le, C, Tatulych, S, Griffiths, C E M & Hampton, P J 2017, ' Treatment Patterns and Outcomes among Adults Admitted to Hospital in the United Kingdom (UK) due to Plaque or Erythrodermic Psoriasis ', The British journal of dermatology . https://doi.org/10.1111/bjd.15270

The National Institute for Health and Care Excellence (NICE) identified treatment of moderate-to-severe psoriasis as an area for research.(1-2) No recent studies have assessed treatment patterns and outcomes among patients hospitalised for psoriasis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3818::d1617be905bf76969f894ecbafa3b635
https://pure.manchester.ac.uk/ws/files/50907411/bjd15270.pdf

Zobrazit plný text záznamu

Akademický článek

Response rates and minimal residual disease outcomes as potential surrogates for progression-free survival in newly diagnosed multiple myeloma.

Autor: Daniele P; Purple Squirrel Economics, a Cytel Company, Montreal, Canada., Mamolo C; Pfizer Inc., Groton, Connecticut, United States of America., Cappelleri JC; Pfizer Inc., Groton, Connecticut, United States of America., Bell T; Pfizer Inc., New York, New York, United States of America., Neuhof A; Pfizer Pharma GmbH, Berlin, Germany., Tremblay G; Purple Squirrel Economics, a Cytel Company, Montreal, Canada., Musat M; Purple Squirrel Economics, a Cytel Company, New York, New York, United States of America., Forsythe A; Purple Squirrel Economics, a Cytel Company, New York, New York, United States of America.

Publikováno v: PloS one [PLoS One] 2022 May 12; Vol. 17 (5), pp. e0267979. Date of Electronic Publication: 2022 May 12 (Print Publication: 2022).

Zobrazit plný text záznamu

Plný text ve formátu HTML

Effect of tofacitinib withdrawal and re-treatment on patient-reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis

Autor: Griffiths, CEM, Vender, R, Sofen, H, Kircik, L, Tan, H, Rottinghaus, ST, Bachinsky, M, Mallbris, L, Mamolo, C

Publikováno v: Journal of the European Academy of Dermatology and Venereology : JEADV, vol 31, iss 2

BackgroundTofacitinib is an oral Janus kinase inhibitor being investigated for psoriasis. A Phase 3 withdrawal/re-treatment study (NCT01186744; OPT Retreatment) showed tofacitinib re-treatment was effective in patients with chronic plaque psoriasis.O

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::cbd145c4536b389ad26b3bfe50e22ad7
https://escholarship.org/uc/item/91m1n5rt

Zobrazit plný text záznamu

Akademický článek

Cost Effectiveness of Gemtuzumab Ozogamicin in the First-Line Treatment of Acute Myeloid Leukaemia in the UK.

Autor: Russell-Smith TA; Global Oncology, Pfizer Inc, New York, NY, USA. alexander.smith@pfizer.com., Brockbank J; Department of Health Economics, RTI Health Solutions, Manchester, UK., Mamolo C; Global Oncology, Pfizer Inc, Groton, CT, USA., Knight C; Department of Health Economics, RTI Health Solutions, Manchester, UK.

Publikováno v: PharmacoEconomics - open [Pharmacoecon Open] 2021 Dec; Vol. 5 (4), pp. 677-691. Date of Electronic Publication: 2021 Jun 28.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání